Low-dose naltrexone (LDN) has emerged as one of the most promising agents in this area, working through glial cell modulation to reduce neuroinflammation and through toll-like receptor pathways to quiet abnormal immune activation
At the 12-month follow-up : 87.5% of patients reported significant relief defined as 50% reduction in baseline pain scores Mean VAS pain score dropped from 7.2 at baseline to 2.8 at 12 months KOOS (Knee Injury and Osteoarthritis Outcome Score) improved across all subscales: pain, symptoms, activities of daily living, sport/recreation, and quality of life No serious adverse events were reported across the treatment period The durability of the response at 12 months is particularly notable
Most Epitalon research from Russian sources with limited Western validation
Pejman Katiraei Yeah, I mean, I'm sure, like you, I see mast cells as the central piece to not all of this, but a very large part of essentially what's perpetuating the problems
Different peptides target different pathways
